Introduction. Postcovid syndrome is an urgent problem, due to its high frequency regardless of the severity of the infection and the age of the patient.Aim. To evaluate the efficacy and safety of the use of a dietary supplement Metabovit® Healthy Sleep with Glycine and Zinc in patients with postcovid syndrome.Materials and methods. 50 patients with postcovid syndrome were included in the study, after randomization, Metabovit® Healthy Sleep was added to therapy in group 1 (2 tablets 3 times a day), in group 2 patients received basic therapy for chronic diseases. The duration of observation was 21 days. Before and after the end of the study all patients underwent clinical and neuropsychological examination, which included: complaint analysis, the “Schulte tables” test, a verbal association test, a Trail Making Test, an MFI-20 self-questionnaire, a Reader test, a questionnaire on the level of life exhaustion, a hospital scale of anxiety and depression (HADS).Results. In the group of patients receiving Metabovit® Healthy Sleep 2 tablets 3 times a day, in comparison with the control group, the overall MFI-20 self-questionnaire score sugnificantly (p < 0.001) decreased by 16 [-19, -8] to 59 [52; 63] points performance time of "Schulte tables" test decreased by more than 13 seconds; performance time of the Trail Making Test was 26 seconds faster in part A and 40 seconds faster in part B, in the verbal association test, the results reached normative values for most participants; stress levels decreased by almost 25% in men and 11% in women; the indicator of life exhaustion decreased by 22%; the level of anxiety (HADS score) decreased by 5 [-7; -3] points which led to the normalization of this indicator in almost all participants of the group. By the end of the study, no significant changes in the studied parameters were detected in patients of the control group.Conclusion. In the group of patients who received the Metabovit® Healthy Sleep dietary supplement, there was a significant positive dynamics and regression of most of the symptoms of postcovid syndrome, in comparison with the control group.